Z-VAD-FMK is a cell-permeable pan-caspase inhibitor that irreversibly binds to the catalytic site of caspase proteases and can inhibit induction of apoptosis. Z-VAD-FMK has been shown to block TGF-beta1-induced apoptosis and inhibit CPP32-like protease activity in lysates in the pretreatment of hepatocytes.
- Broad-spectrum caspase inhibitor
- Potent inhibitor of caspase-dependent inflammasomes
- Blocks the induction of apoptosis
- Each lot is highly pure (≥95%) and functionally tested
|Alternative Names||Z-Val-Ala-Asp(OMe)-FMK; Z-VAD(OMe)-FMK;|
|Chemical Name||L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2- oxoethyl)-2-oxopropyl]-|
|Purity||≥98% by HPLC|
|Physical Appearance||White to off-white (Solid)|
|Storage||Powder: - 20°C for 3 years and 4°C for 2 years|
|Quality Statement||This product is for Research Use Only and is not intended for therapeutic or diagnostic use.|
- Z-VAD-FMK Technical Data Sheet
- Brochure: Small Molecules for Stem Cell Research
- FAQs: General Guide for Small Molecules
References and Publications
- Kawasaki M, et al. (2000) Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am J Pathol. 157(2):597- 603.
- Park S, et al. (2004) Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 35(10):2412-7.
- Inayat-Hussain SH, et al. (1997) Processing/activation of CPP32-like proteases is involved in transforming growth factor beta1-induced apoptosis in rat hepatocytes. Hepatology. 25(6):1516-26.